Author’s response to reviews

Title: The hOGG1 Ser326Cys Polymorphism and Prostate Cancer Risk: A Meta-Analysis of 2524 cases and 3234 controls

Authors:

Hongtuan Zhang (zhtlml@163.com)
Yong Xu (xymnwk@163.com)
Zhihong Zhang (lfmnwk@163.com)
Liang Li (liliang200901@126.com)

Version: 4 Date: 17 June 2011

Author’s response to reviews:

Dear Editors,

We would like to submit the manuscript entitled “The hOGG1 Ser326Cys Polymorphism and Prostate Cancer Risk: A Meta-Analysis of 2524 cases and 3234 controls”, which we wish to be considered for publication in BMC cancer. All authors have read and approve this version of the article, and due care has been taken to ensure the integrity of the work. No part of this paper has published or submitted elsewhere. No conflict of interest exits in the submission of this manuscript. All authors have made a significant contribution to the findings and methods in the paper.

We believe that two aspects will make it interesting to general readers of the BMC cancer. First, to the best of our knowledge, it is the first systematic review that has investigated the association of hOGG1 Ser326Cys polymorphism and prostate cancer. Second, our meta-analysis evaluated the association between Ser326Cys polymorphism and prostate cancer risk and revealed that hOGG1 polymorphism Ser326Cys was associated with a trend of decreased prostate cancer risk in mixed population.

Thank you for your attention to our paper.

Sincerely yours,

Yong Xu